Drug-loaded composite materials based on polysaccharide carriers for alleviating myocardial cell damage
Related Experiment Video
Updated: May 9, 2026
A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
Published on: June 14, 2015
Lingling Sun1, Lifeng Zhu2, Xiaoci Li2
1Department of Cardiology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China; Department of Cardiology, Yizheng Hospital of Chinese Medicine, Yizheng, Jiangsu, China.
Abstract:
Heart failure, a leading cause of mortality among cardiovascular disease patients, is primarily a consequence of chronic heart failure (CHF) and myocardial tissue damage associated with apoptosis. Leveraging the pharmacological success of Dapagliflozin, an SGLT-2 inhibitor known for reducing glucose reabsorption and its preventative efficacy against cardiovascular diseases, we have engineered and synthesized a novel derivative, compound 2, to enhance therapeutic outcomes. Furthermore, we utilized chitosan (CS) as a carrier matrix and integrated a bioactive compound, compound 1, synthesized from actinomycetes, to develop an antimicrobial drug delivery material, CS-1, designated for the administration of compound 2 (CS-1@2), which exhibits pH-responsive antimicrobial effects. The physicochemical properties, in vitro biological characteristics, and bioactivity of CS-1@2 were rigorously evaluated. Results indicated that CS-1 possesses a porous structure, facilitating accelerated release of compound 2 in mildly acidic conditions. In vitro cellular assays were conducted, establishing a CHF model using doxorubicin-induced AC16 cardiomyocytes. This study aims to elucidate the mechanisms through which CS-1@2 mitigates doxorubicin-induced damage in AC16 myocardial cells, highlighting its potential in CHF management. This study lays a promising foundation for targeted therapy of chronic heart failure (CHF) and promotes its translational application in personalized cardiovascular medicine.
Insights
Researchers developed a novel drug delivery system, CS-1@2, for chronic heart failure (CHF) management. This system effectively mitigates doxorubicin-induced damage in heart cells, showing promise for cardiovascular medicine.
Area of Science:
- Cardiovascular Medicine
- Drug Delivery Systems
- Biomaterials
Background:
- Chronic heart failure (CHF) is a major cause of cardiovascular mortality, often linked to myocardial apoptosis.
- Dapagliflozin, an SGLT-2 inhibitor, shows cardiovascular benefits.
- Novel therapeutic strategies are needed for CHF management.
Purpose of the Study:
- To engineer and evaluate a novel drug delivery system (CS-1@2) for enhanced chronic heart failure (CHF) therapy.
- To investigate the pH-responsive antimicrobial properties and drug release characteristics of CS-1@2.
- To assess the protective effects of CS-1@2 against doxorubicin-induced myocardial damage in vitro.
Main Methods:
- Synthesis and characterization of a novel Dapagliflozin derivative (compound 2) and a chitosan-based antimicrobial material (CS-1).
- Development of a pH-responsive drug delivery system (CS-1@2) for compound 2.
- Evaluation of physicochemical properties, in vitro release kinetics, and bioactivity of CS-1@2.
- Establishment of a doxorubicin-induced chronic heart failure (CHF) model using AC16 cardiomyocytes for in vitro assays.
Main Results:
- CS-1@2 demonstrated a porous structure with accelerated release of compound 2 under mildly acidic conditions.
- The CS-1@2 system exhibited pH-responsive antimicrobial effects.
- In vitro assays showed that CS-1@2 effectively mitigated doxorubicin-induced damage in AC16 myocardial cells.
Conclusions:
- The novel CS-1@2 drug delivery system shows significant potential for managing chronic heart failure (CHF).
- This system offers a promising platform for targeted therapy and personalized cardiovascular medicine.
- Further translational application of CS-1@2 in clinical settings is warranted.
